Literature DB >> 26545048

Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.

Daniel P Cahill1,2, David N Louis2,3, John Gregory Cairncross4,5.   

Abstract

Oligodendroglioma is the quintessential molecularly-defined brain tumor. The characteristic whole-arm loss of the long arm of chromosome 1 and the short arm of chromosome 19 (1p/19q-codeletion) within the genome of these tumors facilitated the reproducible molecular identification of this subcategory of gliomas. More recently, recurrent molecular genetic alterations have been identified to occur concurrently with 1p/19q-codeletion, and definitively identify these tumors, including mutations in IDH1/2, CIC, FUBP1, and the TERT promoter, as well as the absence of ATRX and TP53 alterations. These findings provide a foundation for the consistent diagnosis of this tumor type, upon which a generation of clinical investigators have assembled a strong evidence base for the effective treatment of this disease with radiation and chemotherapy.

Entities:  

Keywords:  1p/19q loss; CIC mutation; FUBP1 mutation; IDH mutation; TERT mutation; oligodendroglioma

Mesh:

Substances:

Year:  2015        PMID: 26545048      PMCID: PMC6082339          DOI: 10.2217/cns.15.32

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  60 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Capicua DNA-binding sites are general response elements for RTK signaling in Drosophila.

Authors:  Leiore Ajuria; Claudia Nieva; Clint Winkler; Dennis Kuo; Núria Samper; María José Andreu; Aharon Helman; Sergio González-Crespo; Ze'ev Paroush; Albert J Courey; Gerardo Jiménez
Journal:  Development       Date:  2011-01-26       Impact factor: 6.868

3.  Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading.

Authors:  R A Prayson; D P Agamanolis; M L Cohen; M L Estes; B K Kleinschmidt-DeMasters; F Abdul-Karim; S P McClure; B A Sebek; R Vinay
Journal:  J Neurol Sci       Date:  2000-04-01       Impact factor: 3.181

4.  DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.

Authors:  Michael D Blough; Mohammad Al-Najjar; Charles Chesnelong; Carmen E Binding; Alexandra D Rogers; H Artee Luchman; John J Kelly; Larry Fliegel; Olena Morozova; Stephen Yip; Marco Marra; Samuel Weiss; Jennifer A Chan; J Gregory Cairncross
Journal:  Ann Neurol       Date:  2012-06       Impact factor: 10.422

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

7.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

8.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

9.  Molecular classification of low-grade diffuse gliomas.

Authors:  Young-Ho Kim; Sumihito Nobusawa; Michel Mittelbronn; Werner Paulus; Benjamin Brokinkel; Kathy Keyvani; Ulrich Sure; Karsten Wrede; Yoichi Nakazato; Yuko Tanaka; Anne Vital; Luigi Mariani; Robert Stawski; Takuya Watanabe; Umberto De Girolami; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 5.770

10.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

View more
  17 in total

1.  Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.

Authors:  Candice D Carpenter; Iyad Alnahhas; Javier Gonzalez; Pierre Giglio; Vinay K Puduvalli
Journal:  Expert Rev Neurother       Date:  2019-05-27       Impact factor: 4.618

2.  Perinatal lead (Pb) exposure results in sex and tissue-dependent adult DNA methylation alterations in murine IAP transposons.

Authors:  L Montrose; C Faulk; J Francis; D C Dolinoy
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

Review 3.  Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.

Authors:  Marta Penas-Prado; Jing Wu; Daniel P Cahill; Daniel J Brat; Joseph F Costello; Paul G Kluetz; J Gregory Cairncross; Martin van den Bent; Roel G W Verhaak; Orwa Aboud; Peter Burger; Susan M Chang; Christine Cordova; Raymond Y Huang; Lindsay S Rowe; Martin J B Taphoorn; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Adv       Date:  2019-12-06

Review 4.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

Review 5.  Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.

Authors:  Michael W Ruff; Joon Uhm
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

6.  Identification of CRYAB+ KCNN3+ SOX9+ Astrocyte-Like and EGFR+ PDGFRA+ OLIG1+ Oligodendrocyte-Like Tumoral Cells in Diffuse IDH1-Mutant Gliomas and Implication of NOTCH1 Signalling in Their Genesis.

Authors:  Meera Augustus; Donovan Pineau; Franck Aimond; Safa Azar; Davide Lecca; Frédérique Scamps; Sophie Muxel; Amélie Darlix; William Ritchie; Catherine Gozé; Valérie Rigau; Hugues Duffau; Jean-Philippe Hugnot
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

7.  Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.

Authors:  Débora Cabral de Carvalho Corrêa; Francine Tesser-Gamba; Indhira Dias Oliveira; Nasjla Saba da Silva; Andrea Maria Capellano; Maria Teresa de Seixas Alves; Frederico Adolfo Benevides Silva; Patrícia Alessandra Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo
Journal:  J Neurooncol       Date:  2021-09-27       Impact factor: 4.130

Review 8.  Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.

Authors:  Daniel P Cahill
Journal:  Neurosurg Clin N Am       Date:  2020-11-05       Impact factor: 2.509

9.  Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.

Authors:  Jonathan So; Yasin Mamatjan; Gelareh Zadeh; Kenneth Aldape; Fabio Y Moraes
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

Review 10.  Current status of biomarker research in neurology.

Authors:  Jiri Polivka; Jiri Polivka; Kristyna Krakorova; Marek Peterka; Ondrej Topolcan
Journal:  EPMA J       Date:  2016-07-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.